Analysis of whether the side effects of Tepotinib (Tuodekang) are milder than traditional chemotherapy drugs

Tepotinib (trade name TEPMETKO) is an oral METTyrosine kinase inhibitor, mainly used to treat METExon14Patients with advanced or metastatic non-small cell lung cancer (NSCLC) driven by >skipping mutations (METex14). Its mechanism of action is to selectively inhibit the MET signaling pathway and block tumor cell proliferation and metastasis, thereby achieving targeted therapeutic effects. Unlike traditional chemotherapy drugs, tepotinib targets specific gene mutations and has precise targeting properties. Therefore, in theory, its side effect spectrum is significantly different from traditional chemotherapy.

Clinical studies have shown that common adverse reactions of tepotinib include edema, nausea, diarrhea, myalgia, mild to moderate liver function abnormalities and elevated serum creatine kinase. Most side effects are grade 1 to 2 and can be effectively controlled through dose adjustment, delayed administration, or symptomatic treatment. The incidence of serious adverse events (grade 3 and above) is relatively low, ranging from 5% to 10%. Overall, the toxicity of tepotinib is highly manageable and well tolerated by patients.

The mechanism of action of traditional chemotherapy drugs (such as paclitaxel, cisplatin, gemcitabine, etc.) is to kill rapidly proliferating tumor cells with a broad spectrum, while also damaging normal rapidly dividing cells, often causing bone marrow suppression, severe nausea and vomiting, hair loss, oral mucositis, and increased risk of infection. In contrast, Tepotinib's side effects are more targeted and will not generally suppress bone marrow or damage other rapidly dividing tissues. Therefore, its side effects and systemic toxicity are significantly lower than traditional chemotherapy, and it is more conducive to long-term treatment and maintenance of quality of life for patients.

In clinical application, for patients with NSCLC who meet the METex14 mutation, tepotinib can be given priority as a first-line or later-line treatment option to reduce treatment-related side effects and improve the patient's quality of life. During use, liver function, blood routine, and edema should be monitored regularly, and dosage adjustments should be made if necessary. Overall, tepotinib has milder side effects and tolerability than traditional chemotherapy drugs, but it still requires individualized management to ensure both efficacy and safety.

Reference link:https://www.drugs.com